Published in Ann Rheum Dis on June 01, 2003
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis (2005) 2.62
[Measurement instead of scoring in rheumatology: new quantitative imaging and processing methods in radiology]. Z Rheumatol (2008) 1.39
Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description. Ann Rheum Dis (2004) 0.94
Effects of GSTM1 in rheumatoid arthritis; results from the Swedish EIRA study. PLoS One (2011) 0.88
Feasibility study of semi-automated measurements of finger joint space widths. Rheumatol Int (2010) 0.82
[Computer assisted radiological diagnostics of arthritic joint alterations]. Z Rheumatol (2006) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) (2004) 4.56
Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J (1988) 3.77
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Mechanism of the t(14;18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners. Proc Natl Acad Sci U S A (1987) 3.18
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Ultrasound therapy for calcific tendinitis of the shoulder. N Engl J Med (1999) 2.92
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) (2006) 2.36
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Aneurysmal bone cyst. A population based epidemiologic study and literature review. Clin Orthop Relat Res (1999) 2.22
Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months. Diabetologia (1983) 2.18
Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet (1997) 2.10
Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis (1996) 2.04
Assessing remission in clinical practice. Rheumatology (Oxford) (2007) 1.92
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis (2001) 1.78
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis (2006) 1.77
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis (2005) 1.77
Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis (2002) 1.75
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) (2002) 1.69
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Recruitment of Mycobacterium tuberculosis specific CD4+ T cells to the site of infection for diagnosis of active tuberculosis. J Intern Med (2008) 1.68
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.67
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol (1997) 1.65
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol (2004) 1.65
Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. Arthritis Rheum (1992) 1.61
Fine specificity of anti-Ro(SSA) autoantibodies and clinical manifestations in patients with systemic lupus erythematosus. J Rheumatol (1996) 1.61
Energy metabolism in acute and chronic renal failure. Am J Clin Nutr (1990) 1.60
Diagnostic value of high-resolution B-mode and doppler sonography for imaging of hand and finger joints in rheumatoid arthritis. Arthritis Rheum (2003) 1.59
The diagnosis of meniscal tears in athletes. A comparison of clinical and magnetic resonance imaging investigations. Am J Sports Med (1997) 1.57
Concurrence of sarcoidosis and aortitis: case report and review of the literature. Ann Rheum Dis (2000) 1.57
A comparative trial of three regimens for treating uncomplicated falciparum malaria in Acre, Brazil. J Infect Dis (1988) 1.56
Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis (1994) 1.53
Schnitzler's syndrome--exacerbation after anti-TNF treatment. Rheumatology (Oxford) (2007) 1.52
Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum (1989) 1.48
Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Correlation with clinical features. Am J Med (1982) 1.46
Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) (2008) 1.46
Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum (2009) 1.46
Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.45
High plasma levels of nitrogen oxides are associated with severe disease and correlate with rapid parasitological and clinical cure in Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg (1996) 1.45
Subchondral bone and cartilage disease: a rediscovered functional unit. Invest Radiol (2000) 1.44
Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus. J Rheumatol (1994) 1.44
Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol (1996) 1.42
Antinuclear antibodies in patients with chronic idiopathic autoimmune thrombocytopenia followed 2-30 years. Am J Hematol (1989) 1.42
Rheumatoid arthritis and B lymphocyte alloantigen HLA-DRw4. J Rheumatol (1980) 1.41
Lactosorb panel and screws for repair of large orbital floor defects. J Craniomaxillofac Surg (1997) 1.40
[Measurement instead of scoring in rheumatology: new quantitative imaging and processing methods in radiology]. Z Rheumatol (2008) 1.39
Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.38
Responder cells in the human autologous mixed lymphocyte reaction. J Clin Invest (1981) 1.37
Rotator cuff tears in asymptomatic individuals: a clinical and ultrasonographic screening study. Eur J Radiol (2004) 1.36
Quantification of axial alignment of the lower extremity on conventional and digital total leg radiographs. Eur Radiol (2004) 1.35
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
Interaction of fibronectin with C1q and its collagen-like fragment (CLF). FEBS Lett (1981) 1.33
Human lymphocytes with either the OKT4 or OKT8 phenotype produce interleukin 2 in culture. J Clin Invest (1982) 1.33
Near-patient assays for diagnosis of influenza virus infection in adult patients. Clin Microbiol Infect (2009) 1.32
Reciprocal regulation of Th1- and Th2-cytokine-producing T cells during clearance of parasitemia in Plasmodium falciparum malaria. Infect Immun (1998) 1.31
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
HLA antigens in inflammatory bowel disease. Gastroenterology (1982) 1.31
Changes in bone mineral density in the proximal femur after cementless total hip arthroplasty. A five-year longitudinal study. J Bone Joint Surg Br (2004) 1.30
Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis (2007) 1.30
The human autologous mixed lymphocyte reaction. III. Immune circuits. J Immunol (1982) 1.27
In vitro correction of the interleukin 2 defect of autoimmune mice. Eur J Immunol (1983) 1.27
Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest (1992) 1.26
Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest (2004) 1.26
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis (2003) 1.25
Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis (2009) 1.25
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis (2004) 1.24
Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus (2004) 1.23
Toll-like receptors and chondrocytes: the lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of toll-like receptor 4 and antagonized by bone morphogenetic protein 7. Arthritis Rheum (2007) 1.23
High efficacy of short-term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic. Antimicrob Agents Chemother (1995) 1.21
The human autologous mixed lymphocyte reaction. I. Suppression by macrophages and T cells. J Immunol (1981) 1.21
Prediction of accelerated cure in Plasmodium falciparum malaria by the elevated capacity of tumor necrosis factor production. Am J Trop Med Hyg (1995) 1.21
Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol (1993) 1.20
Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.18
Elevated serum levels of IL-10 and IFN-gamma in patients with acute Plasmodium falciparum malaria. Clin Immunol Immunopathol (1995) 1.18
Imaging features of iliopsoas bursitis. Eur Radiol (2001) 1.18